• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide

tetano

Editor, Senior Moderator
Eur J Med Chem. 2020 Mar 13;194:112223. doi: 10.1016/j.ejmech.2020.112223. [Epub ahead of print]
N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.


de Castro S[SUP]1[/SUP], Ginex T[SUP]2[/SUP], Vanderlinden E[SUP]3[/SUP], Laporte M[SUP]3[/SUP], Stevaert A[SUP]3[/SUP], Cumella J[SUP]1[/SUP], Gago F[SUP]4[/SUP], Camarasa MJ[SUP]1[/SUP], Luque FJ[SUP]5[/SUP], Naesens L[SUP]6[/SUP], Velazquez S[SUP]7[/SUP].

Author information




Abstract

The influenza virus hemagglutinin (HA) is an attractive target for antiviral therapy due to its essential role in mediating virus entry into the host cell. We here report the identification of a class of N-benzyl-4,4,-disubstituted piperidines as influenza A virus fusion inhibitors with specific activity against the H1N1 subtype. Using the highly efficient one-step Ugi four-component reaction, diverse library of piperidine-based analogues was synthesized and evaluated to explore the structure-activity relationships (SAR). Mechanistic studies, including resistance selection with the most active compound (2) demonstrated that it acts as an inhibitor of the low pH-induced HA-mediated membrane fusion process. Computational studies identified an as yet unrecognized fusion inhibitor binding site, which is located at the bottom of the HA[SUB]2[/SUB] stem in close proximity to the fusion peptide. A direct π-stacking interaction between the N-benzylpiperidine moiety of 2 and F9[SUB]HA2[/SUB] of the fusion peptide, reinforced with an additional π-stacking interaction with Y119[SUB]HA2[/SUB], and a salt bridge of the protonated piperidine nitrogen with E120[SUB]HA2[/SUB], were identified as important interactions to mediate ligand binding. This site rationalized the observed SAR and provided a structural explanation for the H1N1-specific activity of our inhibitors. Furthermore, the HA[SUB]1[/SUB]-S326V mutation resulting in resistance to 2 is close to the proposed new binding pocket. Our findings point to the N-benzyl-4,4,-disubstituted piperidines as an interesting class of influenza virus inhibitors, representing the first example of fusion peptide binders with great potential for anti-influenza drug development.
Copyright ? 2020 Elsevier Masson SAS. All rights reserved.



KEYWORDS:

Fusion peptide inhibitor; Hemagglutinin; Influenza virus; N-Benzyl-4,4,-disubstituted piperidines


PMID:32220685DOI:10.1016/j.ejmech.2020.112223
 
Back
Top Bottom